Omzo vs Maximus: Compare Compounded Semaglutide Plans
Choosing between Omzo vs Maximus comes down to clinician involvement, pricing model, medication sourcing, and regulatory notes. Early verdict: Omzo emphasizes clinician-guided, personalized compounded programs with semaglutide starting at $179, while Maximus positions itself as a lower flat-rate telemedicine option at $132.99 per month and broader state availability.
Explore Omzo clinician-guided plans
How Omzo vs Maximus differ at a glance
Both providers offer compounded semaglutide through telemedicine and U.S. pharmacies, but the three most distinctive differences are pricing model and starting price, clinician oversight and program personalization, and state availability and program scope. Regulatory parity to note: both use compounded medications that are not FDA-approved.
1. Pricing model and transparency
Omzo lists semaglutide starting at $179 and also lists tirzepatide starting at $279, describing medication costs included in fees collected by Omzo. Maximus advertises a low flat rate of $132.99 per month and several references to monthly pricing such as $79.99 and $132.99, with statements like no membership fees and transparent pricing. Maximus explicitly calls its model direct-pay with no insurance billing.
2. Clinician oversight and personalization
Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers and notes that clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make final prescribing decisions. Omzo also states providers may write prescriptions for branded medications that patients must fill themselves. Maximus describes prescriptions approved by licensed doctors and telemedicine access with no clinic visits, offering custom titration included in the monthly or quarterly price unless a 90 day starter pack is used.
3. Medication sourcing, regulatory status, and shipping
Omzo connects patients to a compounded medication program produced by a state-licensed sterile compounding pharmacy and clearly notes these compounded drugs are not FDA-approved and have not been reviewed for safety, effectiveness, or quality. Omzo also says it associates with certified U.S. pharmacies and that medication costs are included in fees collected by Omzo. Maximus states its medications are compounded in US-based pharmacies, filled through trusted U.S. pharmacies, offers free expedited or priority shipping, and also includes the regulatory note that compounded medications are not FDA-approved.
Comparison table: Omzo vs Maximus
| Criteria | Omzo | Maximus |
|---|---|---|
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Flat rate $132.99 per month (advertised) |
| Clinician involvement | Clinician-guided plans reviewed by licensed U.S. providers; third party clinician networks | Prescriptions approved by licensed doctors via telemedicine |
| Medication type | Compounded semaglutide and tirzepatide; may prescribe branded meds for patient to fill | Compounded semaglutide only; limited published detail on tirzepatide availability |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA | Compounded medications are not FDA-approved and not reviewed by FDA |
| Shipping and pharmacies | Fast, discreet delivery; associates with certified U.S. pharmacies; fees include medication costs | Compounded in U.S. pharmacies; free priority or expedited shipping; filled through trusted U.S. pharmacies |
| State availability and refunds | Users should confirm state availability; eligibility and state coverage may change | Available in all 50 states except Mississippi; medication costs fully refunded if not approved |
Program experience and guarantees
Omzo includes patient experience copy such as a three month example and explicitly warns that results vary and are not guaranteed. Omzo notes it is not a medical practice and that provider review determines eligibility. Maximus cites published study averages in landing content and includes a stated refund policy if you are not approved for treatment, but does not publish an outcome guarantee.
Visit Maximus for flat-rate plans
Clinical decisions, personalization, and follow up
Omzo presents clinician-guided care as central, with providers making final determinations about prescribing and possibly issuing branded prescriptions patients must fill. Maximus highlights straightforward telemedicine approvals, the ability to work with providers on dosing if you have prior GLP-1 documentation, and included custom titration except with certain starter packs.
Check Maximus availability and protocol
Final verdict: Omzo vs Maximus
In summary, Omzo suits people seeking clinician-guided, personalized programs with options including compounded semaglutide and tirzepatide and who accept that some prescriptions may be for branded drugs to be filled separately. Maximus is aimed at people prioritizing a lower flat monthly price, direct-pay telemedicine access, and simple pharmacy fulfillment through trusted U.S. pharmacies, with broad state availability except Mississippi and a refund if not approved.
Choose Omzo if…
- You want clinician-guided plans reviewed by licensed U.S. providers and explicit program personalization.
- You are comfortable with compounded medications that are not FDA-approved and want access to tirzepatide options.
- You prefer plans where medication costs may be included in fees collected by the platform.
Choose Maximus if…
- You want a lower flat-rate telemedicine option at $132.99 per month with simple direct-pay pricing.
- You value prescriptions approved by licensed doctors, U.S. pharmacy fulfillment, and availability in most states.
When weighing Omzo vs Maximus, confirm eligibility, state availability, exact costs, and renewal terms with each provider before enrolling, since the evidence supplied shows differences in pricing, clinician model, medication options, and state coverage.